Acumen insider plans sale of 5,102 ABOS shares

Acumen Pharmaceuticals insider Daniel O’Connell filed a Form 144 notice to sell common stock of ABOS.

Rhea-AI Filing Summary

Acumen Pharmaceuticals insider Daniel O’Connell filed a Form 144 notice to sell common stock of ABOS. The planned sale covers 5,102 shares of common stock through Merrill Lynch on NASDAQ, with an aggregate market value of $10,031.44 based on the figures shown. These shares were acquired on 01/02/2026 through the vesting of a restricted stock unit award granted under the issuer’s equity compensation plan, with the same date shown for payment.

The notice also discloses that during the past three months O’Connell sold 4,649 shares of Acumen Pharmaceuticals common stock on 01/05/2026 for gross proceeds of $9,163.33. By signing the notice, the seller represents that he does not know of any undisclosed material adverse information about the company’s current or prospective operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Acumen Pharmaceuticals (ABOS) Form 144 filing disclose?

It discloses that Daniel O’Connell intends to sell 5,102 shares of Acumen Pharmaceuticals common stock, using Merrill Lynch as broker on NASDAQ.

How many ABOS shares are covered by the new planned sale?

The planned transaction covers 5,102 shares of Acumen Pharmaceuticals common stock, with an indicated aggregate market value of $10,031.44.

How did the insider acquire the ABOS shares being sold?

The 5,102 shares were acquired on 01/02/2026 through the vesting of a restricted stock unit award granted as part of Acumen Pharmaceuticals’ equity compensation plan.

What recent ABOS stock sales by this person are also reported?

The filing reports that on 01/05/2026, 4,649 shares of Acumen Pharmaceuticals common stock were sold for gross proceeds of $9,163.33.

On which exchange and through which broker are the ABOS shares to be sold?

The notice lists NASDAQ as the securities exchange and Merrill Lynch, located at 225 Liberty St, Floor 37, New York, NY 10281, as the broker.

What representation does the insider make in the ABOS Form 144?

By signing, the seller represents that he does not know any material adverse information about Acumen Pharmaceuticals’ current or prospective operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/06/2026 - 04:40 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001865136
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Acumen Pharmaceuticals, Inc.
SEC File Number	001-40551
Address of Issuer	1210-1220 WASHINGTON STREET SUITE 210 NEWTON MASSACHUSETTS 02465
Phone	617-344-4190
Name of Person for Whose Account the Securities are To Be Sold	OConnell Daniel Joseph
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	5102	10031.44	60573425	01/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/02/2026	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			5102	01/02/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniel OConnell 1210-1220 WASHINGTON STREET SUITE 210 MA 02465	Common stock	01/05/2026	4649	9163.33

144: Remarks and Signature

Remarks
Date of Notice	01/06/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/24/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Daniel OConnell
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)